Essential hypertension is among the most important preclinical conditions of metabolic syndrome and affects nearly 1 billion people worldwide.1,2 The risk to develop essential hypertension seems to be a function of age, triggered by an unhealthy lifestyle with obesity, and physical inactivity as major risk factors.1 Furthermore, dyslipidemia, 3 inflammatory processes, 4 and oxidative stress 5 have been closely linked to this preclinical condition. Although many pathophysiological mechanisms of hypertension have been elucidated, knowledge is scarce about individual metabolic alterations promoting the development of essential hypertension in healthy subjects or subjects in early stages of this condition.Application of metabolomics can contribute to fill this gap and generate further insights into the pathogenesis of hypertension development. Metabolites represent intermediates and end products of cellular processes and are substantial for signaling, structuring of membranes, and catalytic activity. Metabolic alterations associated with development of hypertension, therefore, may be present years before hypertension diagnosis. Hence, investigating metabolic profiles in prospective cohorts is a promising opportunity to improve our knowledge of incident hypertension and to discover novel biomarkers that elucidate early changes in potential pathways.In the US cohort, of 204 metabolites, the metabolite 4-hydroxyhippurate and a metabolic sex steroids pattern were associated with incident hypertension. 6 Another US study using metabolic profiling revealed an association of diacylglycerols, in general, and of the 2 diacylglycerols 16:0/22:5 and 16:0/22:6, in particular, with blood pressure (BP) and incident hypertension. 7 However, to our knowledge, only a few prospective studies have used metabolic profiling to investigate metabolic alterations associated with incident hypertension, 6,7 and thus further studies are necessary to elucidate this promising approach.This study aimed to identify metabolites associated with incident hypertension using data of 127 serum metabolites (Biocrates AbsoluteIDQ p150) determined within the European Prospective Abstract-Metabolomics is a promising tool to gain new insights into early metabolic alterations preceding the development of hypertension in humans. We therefore aimed to identify metabolites associated with incident hypertension using measured data of serum metabolites of the European Prospective Investigation Into Cancer and Nutrition (EPIC)-Potsdam study. Targeted metabolic profiling was conducted on serum blood samples of a randomly drawn EPIC-Potsdam subcohort consisting of 135 cases and 981 noncases of incident hypertension, all of them being free of hypertension and not on antihypertensive therapy at the time of blood sampling. Mean follow-up was 9.9 years. A validated set of 127 metabolites was statistically analyzed with a random survival forest backward selection algorithm to identify predictive metabolites of incident hypertension taking into account important epidemiol...